When MRI offered no clear answer in suspected prostate cancer, the use of prostate-specific membrane antigen (PSMA)-PET/CT showed promise for reducing the number of biopsies without compromising the ...

The third essential use involves assessing patient eligibility for PSMA targeted radionuclide therapy. Although a contrast CT remains helpful for identifying the 15 to 20 percent of cases where low ...

Prostate-specific membrane androgen PET/CT can help clinicians intensify or de-escalate care for men with prostate cancer who have biochemical recurrence following radical prostatectomy.A ...

The PET tracer [ 89 Zr]Zr-girentuximab targets carbonic anhydrase IX (CAIX), a hypoxia-inducible enzyme that is strongly expressed in clear cell renal cell carcinoma (ccRCC). CAIX expression is highly ...

Scans that make prostate cancer cells glow can eliminate the need for invasive biopsies and cut false positive—and they're ...

The 2026 European Association of Urology (EAU) annual meeting featured a plenary prostate cancer session and a presentation by Dr. Renu Eapen discussing the optimal management of de-novo ...

Australian scientists say it could also help reduce the risk of overdiagnosis by determining which cancers are low-risk and will never cause harm.

A scan that makes prostate cancer cells “glow” could halve the number of men needing invasive biopsies, research suggests.

First results of the PRIMARY2 randomized phase III trial support consideration of PSMA PET/CT in diagnostic work-up ...

"Milford Regional Medical Center is a highly respected community hospital with a strong commitment to clinical excellence," said Peter Ferrari, President of Shields Health. We are proud to collaborate ...